Spectrophotometric Estimation of Lomefloxacin Hydrochloride in Pharmaceutical Dosage Form

B. N. SUHAGIA*, S. A. SHAH, I. S. RATHOD, H. M. PATEL AND Y. M. RAO Department of Quality Assurance, L. M. College of Pharmacy, Navrangpura, Ahmedabad–380 009, India.

A simple and sensitive spectrophotometric method has been developed for the estimation of lomefloxacin hydrochloride in its marketed formulations. The method is based on the reaction between the drug and the dichlone, in the presence of crotonaldehyde in dimethylsulfoxide, which produces a blue chromogen with absorption maximum at 645 nm. The good agreement with Beer's law was found in the concentration range of 5-100 μ g/ml. The optimum reaction conditions and other analytical parameters are evaluated. Statistical comparison of the results with those of reported method shows good agreement, and indicated no significant difference in precision. The proposed method was found to be simple, accurate, and reproducible for the routine analysis of the drug in pharmaceutical dosage forms.

Lomefloxacin, a DNA gyrase inhibitor, is a fluorinated 4quinolone analogue of nalidixic acid. Chemically¹⁻², it is 1ethyl-6,8-difluro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4oxo-3-qunoline carboxylic acid. It is used in mild to severe urinary tract infections³. Lomefloxacin is not official in any pharmacopoeia. Literature survey reveals that lomefloxacin is estimated in pharmaceuticals and biological fluids by Spectrophotometric⁴, HPLC⁵⁻⁷. HPTLC⁸, and microbiological assay methods⁹. In the present investigation, an attempt has been made to develop a simple, accurate and reproducible spectrophotometric method for estimation of lomefloxacin in pharmaceutical formulations.

A Double beam Shimadzu 160A UV/vis spectrophotometer with two matched quartz cells of 1 cm light path was employed for the spectral measurement. Lomefloxacin hydrochloride working standard was

*For correspondence

E-mail: patelhary@rediffmail.com

procured as a gift sample from Cadila Pharmaceuticals Limited, Ahmedabad. Other reagents used were of analytical grade, and distilled water was used during the study.

Lomefloxacin hydrochloride (125 mg) was accurately weighed and transferred to a 25 ml volumetric flask, containing a mixture of distilled water (10.0 ml) and glacial acetic acid (2.0 ml). The solution was diluted to 25 ml with acetonitrile. This stock solution (5.0 ml) was further diluted with DMSO in a 25 ml volumetric flask, to obtain the final concentration of 1000 μ g/ml. Dichlone solution (1.5 % w/ v) was prepared by dissolving dichlone (1.5 g) in DMSO, and diluted to 100 ml with the same solvent. Crotonaldehyde solution (20 % v/v) was prepared by using DMSO as the solvent.

In a series of 10 ml volumetric flasks, lomefloxacin standard solution (0.05-1.0 ml, 1000 μ g/ml), dichlone reagent solution (1.0 ml), and crotonaldehyde solution (1.0 ml), were pipetted out successively. The total volume was made up to 4.0 ml

with DMSO. The reaction flasks were allowed to stand at 60° for 30 min. Later, the flasks were cooled to room temperature, and the final volume was adjusted to the mark with dioxane. Absorbance of the colored solution was measured on Shimadzu UV-visible spectrophotometer at 645 nm, against a reagent blank (Fig. 1).

Twenty tablets were weighed accurately, and powdered. The powder equivalent to lomefloxacin (125 mg) was transferred into a 25 ml volumetric flask, containing a mixture of distilled water (10.0 ml) and glacial acetic acid (2.0 ml); the flask was shaken for 5 min, and volume was adjusted to the mark with acetonitrile. The solution was



Fig. 1: Spectrum of the blue chromogen of lomefloxacin hydrochloride in the visible region

TABLE 1: OPTICAL CHARACTERISTICS OF THE PROPOSED METHOD

Parameters	Values
Wavelength for measurement (nm)	645
Beer's Law limit (µg/ml)	5-100
Molar absoptivity(lit/mole/cm)	4.24 × 10 ³
Sandell's sensitivity(µg/ml/cm ² /0.001 abs. unit)) 8.29 × 10 ⁻²
Regression equation (Y ^p)Slope (b)Intercept on	
y-axis (a)	0.01190.0301
Correlation coefficient (r) ^q	0.9956
Relative standard deviation (%) ^s	0.3-3.7
% Recovery	99.10-100.60%

^p means Y=a+bC, where 'C' is concentration in µg/ml and Y is absorbance unit, ^q means five replicate samples, ^s means five replicate samples. filtered through Whatman filter paper No. 40. Rejecting the first few ml, the filtrate (5.0 ml) was diluted to 25 ml with DMSO. The diluted solution was analyzed as mentioned above.

It was known that crotonaldehyde¹⁰ reacts with dichlone and diethylamine, to form a blue chromogen, diethylaminobutadienyl-naphthoquinone, which gives absorption maximum at 625 nm. Lomefloxacin has an amino moiety in its structure. Therefore, the above principle was used for the determination of lomefloxacin in pharmaceutical formulations. The proposed method was based on the reaction of the drug, dichlone, and crotonaldehyde in dimethylsulfoxide, to give a blue chromogen with the absorption maximum at 645 nm. The proposed method is successfully applied for the determination of lomefloxacin in pharmaceutical formulations.

The optical characteristics of lomefloxacin hydrochloride, such as Beer's law limit, Sandell's sensitivity, molar extinction coefficient, and percent relative standard deviation of the proposed method for the determination of lomefloxacin, are tabulated in Table 1. The Tcal and Fcal values of the proposed method were found to be 0.2034 and 0.6189, respectively (Ttab value = 4.30 and Tcal value = 18.50), which indicated no significant difference between two methods. The recovery was calculated by the addition of pure drug to the previously analyzed pharmaceutical preparations. The results of the analysis of the tablet formulations are shown in Table 2. The effective recovery confirmed the accuracy and the specificity of the proposed method, and the lack of interference from the common excipients, film coating materials, and the colorant used in the manufacture of tablets. This method is particularly useful for routine inprocess quality control for its pharmaceutical preparations.

REFERENCES

1. Reynolds, J.E.F., Eds., In; Martindale: The Extra Pharmacopoeia, 30th

TABLE 2: ANALYSIS OF PHARMACEUTICAL FORMULATIONS

Formulations	Label claim mg/tablet	% Content found by		Percent recovery by proposed method ^u
		Proposed method	HPLC method⁵	
Tablet -1	400	101.90	99.26	99.10
Tablet -2	400	106.60	106.20	100.12
Tablet -3	400	104.60	103.79	100.60

^u means three replicate samples, Tablet-1 stands for tablet of Torrent pharmaceuticals Ltd., Ahmedabad (brand name-Lomef 400, strength-400 mg), Tablet-2 stands for tablet of IPCA, Mumbai (brand name-Lomflox, strength-400 mg) and Tablet-3 stands for tablet of Intas pharmaceuticals Ltd., Ahmedabad (brand name-Lomitas, strength-400 mg).

www.ijpsonline.com

Edn., The Pharmaceutical Press, London, 1994, 179.

- Budavari, S. Eds., In; The Merck Index, 11th Edn., Merck and Co. Inc., Whitehouse Station, N.J., 1989, 875.
- Physicians Desk Reference, 48th Edn., Medical Economics Company Inc., Montvale, N.J., 1994, 2213.
- Rajasekaran, A., Jaykar, B., DhanaLakshmi, S., Deepalakhsmi, M. and Beulah, V.I., Indian J. Pharm. Sci., 1998, 60, 236.
- Nagashima, M., Kenkyu Nenpo-Tokyyo-toritsu and Eisei kenkyusho, 44, 71, 1993.
- 6. Li, Kangle and Zhongguo Yaoke Xuebao, 25, 231, 1994.
- 7. Shibl, A.M., Ashraf, A.K., Abdel-Kader, F.T. and Ahmed A.A., J. Clin. Pharmacol. Ther., 16, 353, 1991.
- 8. Shah, S.A., Rathod, I.S., Savle, S.S. and Patel, D.R., J. Pharm.

Biomed. Anal., 2002, 30, 1319.

- Chawla, J.L., Sodhi, R.A. and Sane, R.T., Indian Drugs, 1997, 34, 512.
- 10. Buckely, D., Dunstan, S. and Henbest, H. B., J. Chem. Soc., 1957, 3032.

Accepted 18 March 2006 Revised 26 May 2005 Received 3 February 2005 Indian J. Pharm. Sci., 2006, 68 (2): 247-249